Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
PSP websites where patients could be on multiple drugs
-
Hello,
I am curious if there are any rules against having a drop down where patients can select that they are taking multiple drugs that are covered by a PSP.
In a portfolio PSP website we are designing, 2 drugs are covered and we have the patients select which medication they are on. Client has highlighted some patients may be on both drugs. Can we have a patient select that they are on both drugs? -
Hello,
I am curious if there are any rules against having a drop down where patients can select that they are taking multiple drugs that are covered by a PSP.
In a portfolio PSP website we are designing, 2 drugs are covered and we have the patients select which medication they are on. Client has highlighted some patients may be on both drugs. Can we have a patient select that they are on both drugs?Hello @reed-wigs
Theoretically it is possible, however there are several considerations. For example, if the PSP is therapeutic area specific, it would create a link to the other brand for which patients only on one product are not on and would not be acceptable. If the PSP is not therapeutic area specific, it would require verification that the patient was on both products and within the PSP, the content would need to have been reviewed and approved in the context of both products. If it was therapeutic area specific, the content would still require review in the context of both brands. If the products are in different therapeutic areas and the content is different based on the product, there would need to be clear delineation between therapeutic content. These are just some considerations.
We would suggest that you submit for an opinion so that we may assess and provide direction in the context of the specific program and application.
